Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amphotericin B

FDA-approved product (ointment, topical), marketed as Abelcet, Ambisome, Amphotec and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amphotericin B
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Cryptococcal meningitis
  • Cryptococcosis
  • Fungal infectious disease
  • Histoplasmosis
  • Infection
  • Mucormycosis
  • Sporotrichosis
  • Visceral Leishmaniasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antibiotics
FDA pharmacologic class
Lipid-based Polyene Antifungal; Polyene Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB04; WHO ATC A07AA07; WHO ATC G01AA03; WHO ATC J02AA01; FDA class Lipid-based Polyene Antifungal; FDA class Polyene Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Open Amphotericin B in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amphotericin B with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

    NCT07261150 · start 2026-10-01

    Registered record
    Registry ID
    NCT07261150
    Conditions
    Histoplasmosis
    Interventions
    LAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-12-31
    Enrolment
    664

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHistoplasmosis
    InterventionLAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    PhasePhase 3
    Registry statusNot yet recruiting

  • Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy

    NCT07532850 · start 2026-03-30

    Registered record
    Registry ID
    NCT07532850
    Conditions
    Invasive Fungal Infections
    Interventions
    Collection of pharmacokinetic samples to explore the pharmacokinetic characteristics in severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-30
    Completion
    2027-06-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    InterventionCollection of pharmacokinetic samples to explore the pharmacokinetic characteristics in severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

    NCT07300553 · start 2026-01-02

    Registered record
    Registry ID
    NCT07300553
    Conditions
    IBD; Crohn Disease; Ulcerative Colitis (UC)
    Interventions
    Vancomycin /Amphotericin B (Fungizone®) /Gentamicine 80 mg; Inulin/Inulin C13
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-02
    Completion
    2027-08
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIBD; Crohn Disease; Ulcerative Colitis (UC)
    InterventionVancomycin /Amphotericin B (Fungizone®) /Gentamicine 80 mg; Inulin/Inulin C13
    PhasePhase 2
    Registry statusRecruiting

  • Human Bioequivalence Study of Liposomal Amphotericin B for Injection

    NCT06983665 · start 2025-05-25

    Registered record
    Registry ID
    NCT06983665
    Conditions
    Invasive Fungal Infections; Neutropenic Fever; Visceral Leishmaniasis
    Interventions
    Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.); Reference product (AmBisome®, Astellas Pharma US Inc.)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-05-25
    Completion
    2026-03-09
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections; Neutropenic Fever; Visceral Leishmaniasis
    InterventionTest product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.); Reference product (AmBisome®, Astellas Pharma US Inc.)
    PhaseNot applicable
    Registry statusCompleted

  • Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases

    NCT07135778 · start 2025-05-19

    Registered record
    Registry ID
    NCT07135778
    Conditions
    Invasive Fungal Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-05-19
    Completion
    2026-12-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

    NCT06926569 · start 2025-05-01

    Registered record
    Registry ID
    NCT06926569
    Conditions
    HIV/AIDS-associated Talaromycosis
    Interventions
    Amphotericin B; AmBisome
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2026-05-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS-associated Talaromycosis
    InterventionAmphotericin B; AmBisome
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

    NCT07185503 · start 2025-03-25

    Registered record
    Registry ID
    NCT07185503
    Conditions
    Mucormycosis in Hematologic Malignancies
    Interventions
    liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2027-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis in Hematologic Malignancies
    Interventionliposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    PhaseNot recorded
    Registry statusRecruiting

  • A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis

    NCT06447402 · start 2024-06-03

    Registered record
    Registry ID
    NCT06447402
    Conditions
    Chronic Pulmonary Aspergillosis; CPA; Aspergilloma
    Interventions
    Normal saline; Amphotericin B deoxycholate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-03
    Completion
    2026-08-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis; CPA; Aspergilloma
    InterventionNormal saline; Amphotericin B deoxycholate
    PhasePhase 3
    Registry statusUnknown

  • Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model

    NCT05589012 · start 2023-11-01

    Registered record
    Registry ID
    NCT05589012
    Conditions
    Zika Virus Infection
    Interventions
    Cell line and virus; Infection of human placental culture explants; Determination of viral load in tissues by qRT-PCR
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2023-11-01
    Completion
    2024-04-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionZika Virus Infection
    InterventionCell line and virus; Infection of human placental culture explants; Determination of viral load in tissues by qRT-PCR
    PhaseNot recorded
    Registry statusWithdrawn

  • Drug Nephrotoxicity Amelioration by N-acetylcysteine

    NCT06122311 · start 2023-08-25

    Registered record
    Registry ID
    NCT06122311
    Conditions
    Drug-Induced Nephropathy
    Interventions
    N Acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-08-25
    Completion
    2024-06-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Nephropathy
    InterventionN Acetylcysteine
    PhaseNot applicable
    Registry statusCompleted

  • A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

    NCT05707832 · start 2023-03-30

    Registered record
    Registry ID
    NCT05707832
    Conditions
    Invasive Candidiasis; Invasive Aspergillosis
    Interventions
    Amphotericin B cholesteryl Sulfate Complex for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-30
    Completion
    2025-03-31
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis; Invasive Aspergillosis
    InterventionAmphotericin B cholesteryl Sulfate Complex for Injection
    PhasePhase 3
    Registry statusCompleted

  • Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

    NCT06413056 · start 2022-10-20

    Registered record
    Registry ID
    NCT06413056
    Conditions
    Neonatal Infection; Invasive Fungal Infections
    Interventions
    Micafungin; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-10-20
    Completion
    2023-08-30
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Infection; Invasive Fungal Infections
    InterventionMicafungin; Amphotericin B
    PhasePhase 4
    Registry statusCompleted

  • Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

    NCT05471063 · start 2022-08-22

    Registered record
    Registry ID
    NCT05471063
    Conditions
    Cryptococcal Meningitis
    Interventions
    Amphotericin B Colloidal Dispersion; flucytosine; fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-08-22
    Completion
    2023-04-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis
    InterventionAmphotericin B Colloidal Dispersion; flucytosine; fluconazole
    PhaseNot applicable
    Registry statusUnknown

  • Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

    NCT05468372 · start 2022-07-01

    Registered record
    Registry ID
    NCT05468372
    Conditions
    Mucormycosis; Pulmonary (Etiology)
    Interventions
    Posaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2026-02-01
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis; Pulmonary (Etiology)
    InterventionPosaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    PhasePhase 2
    Registry statusCompleted

  • World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

    NCT06267326 · start 2021-05-23

    Registered record
    Registry ID
    NCT06267326
    Conditions
    Mucormycosis; Rhinocerebral (Etiology); COVID-19
    Interventions
    debridment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-05-23
    Completion
    2023-08-21
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis; Rhinocerebral (Etiology); COVID-19
    Interventiondebridment
    PhasePhase 1 / Phase 2
    Registry statusCompleted